Anti-GM-CSF Monoclonal Antibody 400mg
BiologicalAnti-GM-CSF Monoclonal Antibody 400mg
NCT Number: NCT01603277
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
Looking for future studies?
Notify Me16 year–75 year
All sexes
Interventional
Phase 2
Cairns, Queensland, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Anti-GM-CSF Monoclonal Antibody 400mg
Normal Saline
Time frame: Baseline to Week 24
Time frame: Week 24
Time frame: Week 24
Time frame: Week 24
Humanigen, Inc.
Industry
A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
Acronym: KB003-04
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07191535
Asthma, Asthma (Diagnosis)
View Trial DetailsNCT06422663
Moderate-to-Severe Asthma
Baoding, China
View Trial DetailsNCT01678222
Allergic Inflammation, Asthma
Research Triangle Park, North Carolina, United States
View Trial DetailsNCT03937804
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial Details